Minimally invasive surgery for advanced ovarian cancer: a pilot randomized trial
Ended Project Grant Awarded Last action
- Award ID
- W81XWH2211060
- Recipient
-
The General Hospital Corporation UEI FLJ7DQKLL226 Part of Partners Healthcare System Incorporated
- Awarding agency
-
Medical Command
Department of the Army, Department of Defense
- Obligated
- $930,660
Award facts
- Assistance listing
- 12.420 Military Medical Research and Development
- Completion date
- Place of performance
- Boston, MA 02114, USA
Award details come from USAspending.gov.
About this award
The Massachusetts General Hospital was awarded a $930,660 project grant from the Department of the Army Medical Command under the Military Medical Research and Development federal grant program (CFDA 12.420) to conduct a pilot randomized trial evaluating minimally invasive surgery for advanced ovarian cancer. The goal of the trial is to investigate medical solutions for ovarian cancer treatment through the support of applied biomedical research. Dr. Rauh-Hain of Massachusetts General Hospital will oversee trial accrual, eligibility identification, and communication with the national principal investigator and sub-awardee, the University of Texas M.D. Anderson Cancer Center. The grant period is from September 2022 through September 2026 and will support the planned execution and progress monitoring of the proposed ovarian cancer treatment trial.
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| The Univeristy Of Texas M.d. Anderson Cancer Center | $145,090 |
Quick answers
Who received award W81XWH2211060?
W81XWH2211060 was awarded to The General Hospital Corporation by Medical Command (Department of the Army) on September 23, 2022.
How much is award W81XWH2211060 worth?
$930,660 has been obligated on W81XWH2211060.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award